Impact of DNMT3a Status on Post Induction ...
Type de document :
Compte-rendu et recension critique d'ouvrage
PMID :
Titre :
Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively
Auteur(s) :
Heiblig, Maël [Auteur]
Centre de Recherche en Cancérologie de Lyon [UNICANCER/CRCL]
Hospices Civils de Lyon [HCL]
Université Claude Bernard Lyon 1 [UCBL]
Duployez, Nicolas [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Marceau, Alice [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Lebon, Delphine [Auteur]
HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 [HEMATIM]
CHU Amiens-Picardie
Goursaud, Laure [Auteur]
Etablissement français du sang [Rennes] [EFS Bretagne]
Plantier, Isabelle [Auteur]
Stalnikiewich, Laure [Auteur]
Cambier, Nathalie [Auteur]
Centre hospitalier [Valenciennes, Nord]
Balsat, Marie [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Fossard, Gaelle [Auteur]
Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
Centre de Recherche en Cancérologie de Lyon [UNICANCER/CRCL]
Labussiere-Wallet, Helene [Auteur]
Hospices Civils de Lyon [HCL]
Barraco, Fiorenza [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Ducastelle-Lepretre, Sophie [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Sujobert, Pierre [Auteur]
Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
Huet, Sarah [Auteur]
Hayette, Sandrine [Auteur]
Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
Ghesquieres, Herve [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Hospices Civils de Lyon [HCL]
Thomas, Xavier [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Preudhomme, Claude [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre de Recherche en Cancérologie de Lyon [UNICANCER/CRCL]
Hospices Civils de Lyon [HCL]
Université Claude Bernard Lyon 1 [UCBL]
Duployez, Nicolas [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Marceau, Alice [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Lebon, Delphine [Auteur]
HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 [HEMATIM]
CHU Amiens-Picardie
Goursaud, Laure [Auteur]
Etablissement français du sang [Rennes] [EFS Bretagne]
Plantier, Isabelle [Auteur]
Stalnikiewich, Laure [Auteur]
Cambier, Nathalie [Auteur]
Centre hospitalier [Valenciennes, Nord]
Balsat, Marie [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Fossard, Gaelle [Auteur]
Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
Centre de Recherche en Cancérologie de Lyon [UNICANCER/CRCL]
Labussiere-Wallet, Helene [Auteur]
Hospices Civils de Lyon [HCL]
Barraco, Fiorenza [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Ducastelle-Lepretre, Sophie [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Sujobert, Pierre [Auteur]
Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
Huet, Sarah [Auteur]
Hayette, Sandrine [Auteur]
Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
Ghesquieres, Herve [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Hospices Civils de Lyon [HCL]
Thomas, Xavier [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Preudhomme, Claude [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Titre de la revue :
Blood
Éditeur :
American Society of Hematology
Date de publication :
2020
ISSN :
0006-4971
Mot(s)-clé(s) en anglais :
DNMT3A
NPM1
acute myeloid leukemia
elderly
prognosis
NPM1
acute myeloid leukemia
elderly
prognosis
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Minimal residual disease (MRD) is now a powerful surrogate marker to assess the response to chemotherapy in acute myeloid leukemia (AML). DNMT3A mutation has been associated with adverse outcomes. In this study, we aimed ...
Lire la suite >Minimal residual disease (MRD) is now a powerful surrogate marker to assess the response to chemotherapy in acute myeloid leukemia (AML). DNMT3A mutation has been associated with adverse outcomes. In this study, we aimed to investigate the impact of DNMT3A status on NPM1 MRD predictive value for survival in a retrospective cohort of AML patients aged over 60 years old treated intensively. A total of 138 patients treated for NPM1-mutated AML in two French institutions were analyzed retrospectively. DNMT3A status did not influence the probability of having a ≥ 4log MRD1 reduction after induction. Only 20.4% of FLT3-ITD patients reached ≥ 4log MRD1 reduction compared to 47.5% in FLT3wt cases. A 4log reduction of NPM1 MRD was associated with a better outcome, even in FLT3-ITD mutated patients, independent of the allelic ratio. DNMT3A negative patients who reached a 4log reduction had a superior outcome to those who did not (HR = 0.23; p < 0.001). However, postinduction NPM1 MRD1 reduction was not predictive of OS and LFS in DNMT3Amut patients. These results confirm that post-induction NPM1 MRD1 is a reliable tool to assess disease outcome in elderly AML patients. However, the presence of DNMT3A also identifies a subgroup of patients at high risk of relapse.Lire moins >
Lire la suite >Minimal residual disease (MRD) is now a powerful surrogate marker to assess the response to chemotherapy in acute myeloid leukemia (AML). DNMT3A mutation has been associated with adverse outcomes. In this study, we aimed to investigate the impact of DNMT3A status on NPM1 MRD predictive value for survival in a retrospective cohort of AML patients aged over 60 years old treated intensively. A total of 138 patients treated for NPM1-mutated AML in two French institutions were analyzed retrospectively. DNMT3A status did not influence the probability of having a ≥ 4log MRD1 reduction after induction. Only 20.4% of FLT3-ITD patients reached ≥ 4log MRD1 reduction compared to 47.5% in FLT3wt cases. A 4log reduction of NPM1 MRD was associated with a better outcome, even in FLT3-ITD mutated patients, independent of the allelic ratio. DNMT3A negative patients who reached a 4log reduction had a superior outcome to those who did not (HR = 0.23; p < 0.001). However, postinduction NPM1 MRD1 reduction was not predictive of OS and LFS in DNMT3Amut patients. These results confirm that post-induction NPM1 MRD1 is a reliable tool to assess disease outcome in elderly AML patients. However, the presence of DNMT3A also identifies a subgroup of patients at high risk of relapse.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Collections :
Source :
Fichiers
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124973/pdf
- Accès libre
- Accéder au document
- Accès libre
- Accéder au document